These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29970548)

  • 1. Efficacy-safety of Facilitated Subcutaneous Immunoglobulin in Immunodeficiency Due to Hematological Malignancies. A Single-Center Retrospective Analysis.
    Dimou M; Iliakis T; Maltezas D; Bitsani A; Kalyva S; Koudouna A; Kotsanti S; Petsa P; Papaioannou P; Kyrtsonis MC; Panayiotidis P
    Anticancer Res; 2018 Jul; 38(7):4187-4191. PubMed ID: 29970548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary immune deficiencies.
    Blau IW; Conlon N; Petermann R; Nikolov N; Plesner T
    Expert Rev Clin Immunol; 2016 Jul; 12(7):705-11. PubMed ID: 27156362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations.
    Ponsford M; Carne E; Kingdon C; Joyce C; Price C; Williams C; El-Shanawany T; Williams P; Jolles S
    Clin Exp Immunol; 2015 Dec; 182(3):302-13. PubMed ID: 26288095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases.
    Baumann U; Fasshauer M; Pausch C; Wittkowski H; Hermann C; Pittrow D; Borte M
    Immunotherapy; 2022 Feb; 14(2):135-143. PubMed ID: 34743590
    [No Abstract]   [Full Text] [Related]  

  • 5. Facilitated Subcutaneous Immunoglobulin Treatment Increases the Quality of Life and Decreases the Number of Infections and Hospitalizations in Children with Primary Immunodeficiencies.
    Erbaş Açıcı N; Topyildiz E; Aygün A; Geyik M; Edeer Karaca N; Aksu G; Kutukculer N
    Int Arch Allergy Immunol; 2024; 185(4):382-391. PubMed ID: 38246144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facilitated Subcutaneous Immunoglobulin Replacement Therapy in Clinical Practice: A Two Center, Long-Term Retrospective Observation in Adults With Primary Immunodeficiencies.
    Wiesik-Szewczyk E; Sołdacki D; Paczek L; Jahnz-Różyk K
    Front Immunol; 2020; 11():981. PubMed ID: 32670265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into Patient Experiences with Facilitated Subcutaneous Immunoglobulin Therapy in Primary Immune Deficiency: A Prospective Observational Cohort.
    Yalcin Gungoren E; Yorgun Altunbas M; Dikici U; Meric Z; Eser Simsek I; Kiykim A; Can S; Karabiber E; Yakici N; Orhan F; Cokugras H; Aydogan M; Ozdemir O; Bilgic Eltan S; Baris S; Ozen A; Karakoc-Aydiner E
    J Clin Immunol; 2024 Aug; 44(8):169. PubMed ID: 39098942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study.
    Borte M; Hanitsch LG; Mahlaoui N; Fasshauer M; Huscher D; Speletas M; Dimou M; Kamieniak M; Hermann C; Pittrow D; Milito C
    J Clin Immunol; 2023 Aug; 43(6):1259-1271. PubMed ID: 37036560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Experiences With Facilitated Subcutaneous Immunoglobulin Substitution in Patients With Hypogammaglobulinemia, Using a Three-Step Ramp-Up Schedule.
    Hustad NB; Degerud HM; Hjelmerud I; Fraz MSA; Nordøy I; Trøseid M; Fevang B; Aukrust P; Jørgensen SF
    Front Immunol; 2021; 12():670547. PubMed ID: 34012453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin in elderly patients.
    Paassen PV; Pittrow D; Scheidegger C; Klotsche J; Ellerbroek PM
    Immunotherapy; 2020 Feb; 12(2):131-139. PubMed ID: 32066296
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study.
    Rubinstein A; Mabudian M; McNeil D; Patel NC; Wasserman RL; Gupta S; Carrasco P; Chen J; Garcia E; Nagy A; Yel L
    J Clin Immunol; 2024 Aug; 44(8):181. PubMed ID: 39158670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulin replacement therapy discontinuation in patients with antibody deficiency secondary to hematological malignancy.
    Patel V; Cameron DW; Cowan J
    Hematol Oncol; 2021 Oct; 39(4):584-588. PubMed ID: 34288002
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study.
    Ellerbroek PM; Hanitsch LG; Witte T; Lougaris V; Hagen PMV; Paassen PV; Chen J; Fielhauer K; McCoy B; Nagy A; Yel L
    Immunotherapy; 2024; 16(10):679-691. PubMed ID: 38888495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies.
    Na IK; Buckland M; Agostini C; Edgar JDM; Friman V; Michallet M; Sánchez-Ramón S; Scheibenbogen C; Quinti I
    Eur J Haematol; 2019 Jun; 102(6):447-456. PubMed ID: 30801785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults.
    Nagy A; Duff K; Bauer A; Okonneh F; Rondon JC; Yel L; Li Z
    J Clin Immunol; 2023 Dec; 44(1):28. PubMed ID: 38129731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies.
    Li Z; Follman K; Freshwater E; Engler F; Yel L
    Int Immunopharmacol; 2024 Feb; 128():111447. PubMed ID: 38185032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.
    Günther G; Dreger B
    Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HyQvia(
    Angelotti F; Capecchi R; Giannini D; Mazzarella O; Rocchi V; Migliorini P
    Clin Exp Med; 2020 Aug; 20(3):387-392. PubMed ID: 32385734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facilitated subcutaneous immunoglobulin treatment patterns in pediatric patients with primary immunodeficiency diseases.
    Mach-Tomalska M; Pituch-Noworolska A; Bień E; Malanowska M; Machura E; Pukas-Bochenek A; Chrobak E; Pac M; Pietrucha B; Drygała S; Kamieniak M; Kasprzak J; Heropolitańska-Pliszka E
    Immunotherapy; 2024 Apr; 16(6):391-403. PubMed ID: 38362629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases.
    Speth F; Haas JP; Hinze CH
    Pediatr Rheumatol Online J; 2016 Sep; 14(1):52. PubMed ID: 27623619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.